Dustin Thomas, MD
Cardiovascular Disease · Fort Wayne, INNPI 1003078312
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,706 of the $3,306 with a category attached, or 81.8%. 18 manufacturers reported payments, led by Johnson & Johnson at 27.9% of the total. 2025 is the largest year on record at $777, 3.4 times the $231 reported in 2019. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.
Across 128 payments — averaging $25.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$922
- Philips North America LLC$600
- Heartflow, Inc.$510
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$206
- Amgen$190
- AstraZeneca$106
- plus $771 from 12 others
Across 5 payments — averaging $10,235 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$47K
- Pfizer$4K
What the payments were for
- Speaking & faculty fees$60018%
- Food & beverage$2,70682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 49 | $922 |
| Philips North America LLC | 1 | $600 |
| Heartflow, Inc. | 8 | $510 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $206 |
| Amgen | 12 | $190 |
| AstraZeneca | 6 | $106 |
| Kestra Medical Technology Services, Inc. | 2 | $105 |
| Abbott | 1 | $105 |
| Merck | 6 | $104 |
| Novartis | 6 | $94 |
| Boehringer Ingelheim | 5 | $91 |
| Pfizer | 9 | $79 |
| Amarin Pharma, Inc. | 3 | $64 |
| Sanofi-aventis U.S. LLC | 2 | $41 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Boston Scientific | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Abiomed | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hemodynamics Intervention Index$600
- CARDIOMEMS$105
How this compares
$3,306 in reported general payments places this provider in the 50th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 457 | $518,695 |
| Repatha SureclickEvolocumab | 281 | $247,636 |
| XareltoRivaroxaban | 187 | $209,625 |
| EntrestoSacubitril/Valsartan | 106 | $147,498 |
| JardianceEmpagliflozin | 80 | $86,472 |
| Praluent PenAlirocumab | 63 | $47,651 |
| FarxigaDapagliflozin Propanediol | 40 | $29,449 |
| Metoprolol Succinate | 452 | $5,013 |
| Atorvastatin Calcium | 605 | $4,532 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 13 | $3,539 |
| Prasugrel Hcl | 11 | $3,478 |
| Midodrine Hcl | 44 | $3,432 |
| Carvedilol | 505 | $3,366 |
| Ranolazine ErRanolazine | 36 | $3,042 |
| Torsemide | 130 | $2,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $79 | $518,695457 claims |
| Johnson & JohnsonXarelto | $922 | $209,625187 claims |
| NovartisEntresto | $94 | $147,498106 claims |
| Boehringer IngelheimJardiance | $91 | $86,47280 claims |
| AstraZenecaFarxiga | $106 | $29,44940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Fort Wayne
- Michael MirroFort Wayne$57K
- Louis LopezFort Wayne$36K
- Issa KutkutFort Wayne$18K
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Wai LeeElkhart$321K
- Anas SafadiHobart$295K
- Lawrence RinkBloomington$280K
- Vijay RaoIndianapolis$247K
- Steven SteinhublLafayette$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.